Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 12/20 | 0.74 |
| ▸ | PDE4D | Q08499 | 7/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16447027 | 0.89 | PDE4B (0.61) | PDE4BPDE4DPTGS2PTGS1PI4KB | |
| SCHEMBL16446524 | 0.86 | PDE4B (0.79) | PDE4BPDE4DPTGS2PTGS1 | |
| SCHEMBL17784216 | 0.85 | PDE4B (1.00) | PDE4BPDE4DPTGS2PTGS1 | |
| SCHEMBL17784219 | 0.80 | PDE4B (0.59) | PDE4BPDE4DPTGS2PTGS1CA5A | |
| SCHEMBL17784206 | 0.79 | PDE4B (0.79) | PDE4BPTGS2PTGS1PI4KB | |
| SCHEMBL16446217 | 0.77 | PDE4B (0.65) | PDE4BPDE4DPTGS2PTGS1 | |
| SCHEMBL16447005 | 0.76 | PDE4B (0.64) | PDE4BPTGS2PTGS1 | |
| SCHEMBL16447006 | 0.76 | PDE4B (0.64) | PDE4BPTGS2PTGS1 | |
| SCHEMBL16448282 | 0.76 | PDE4B (0.64) | PDE4BPTGS2PTGS1 | |
| SCHEMBL16446574 | 0.75 | PDE4B (0.80) | PDE4BPDE4DPTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3030565-B1 | NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2017-07-19 | — | — | EP | disclosed |
| US-9688683-B2 | Substituted condensed pyrimidine compounds | Grünenthal GmbH (DE) | 2017-06-27 | — | — | US | disclosed |
| EP-3030565-A1 | NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS | Grünenthal GmbH (DE) | 2016-06-15 | — | — | EP | disclosed |
| US-20160152624-A1 | NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS | Grünenthal GmbH (DE) | 2016-06-02 | — | — | US | disclosed |
| WO-2015018534-A1 | NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS | Grünenthal GmbH (DE) | 2015-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152624-A1 | NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS | PDE4A, PDE4B, TYMP | PDE4B 2/4885PDE4D 8/4885PTGS2 599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.